Prof Research published a new market report on viral vectors and plasmid DNA manufacturing market. It presents the largest 10 manufacturers in viral vectors and plasmid DNA manufacturing market. The report is a professional and in-depth study on the current state of the global viral vectors and plasmid DNA manufacturing market. The report provides key statistics on the market for Rice Starch. It is a valuable source of guidance and direction for companies and individuals interested in viral vectors and plasmid DNA manufacturing industry.

The global viral vectors and plasmid DNA manufacturing market were valued to be 1,739.4 million USD in 2021. The viral vectors and plasmid DNA manufacturing production value is anticipated to have grown with a CAGR of 20.7% in the coming years to reach 5,377.5 million USD in 2027.

Catalent is the largest manufacturer of viral vectors and plasmid DNA manufacturing in the world, and it has a market share of 22.1% in value. Catalent, Inc. provides delivery technologies, development and manufacturing solutions for drugs; protein, cell, gene therapy biologics; and consumer health products. Its segments include Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.

Lonza is the second largest manufacturer of viral vectors and plasmid DNA manufacturing in the world, and it has a market share of 12.7% in value. Lonza Group AG is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life science industries. The Company's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as the development of anti-microbial solutions for commercial applications. The Company divides its activities into two segments: Pharma&Biotech and Specialty Ingredients.

Oxford Biomedica is the third largest manufacturer of viral vectors and plasmid DNA manufacturing in the world, and it has a market share of 10.2% in value. Oxford BioMedica Plc is a United Kingdom-based fully integrated, cell and gene therapy company. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. The Company’s segments include the Platform and Product.

FUJIFILM Diosynth Biotechnologies is the fourth largest manufacturer of viral vectors and plasmid DNA manufacturing in the world, and it has a market share of 9.3% in value. UJIFILM Diosynth Biotechnologies is a CDMO partner for life. They focus on combining technical leadership in cell culture, microbial fermentation, and cell and gene therapy with world-class cGMP manufacturing facilities to advance tomorrow’s medicines.